In the current study, combined treatment with GLP-1R agonist exenatide and MR antagonist potassium canrenoate did not show functional benefits on cardiac remodeling and did not result in functional improvement in small and large chronic HF models. This evidence concerns the gene GLP1R and hydrops fetalis.